The short answer
Alpha-MSH has two functionally separable activities: pigmentation through melanocortin receptors, and anti-inflammatory activity at its C-terminus. KPV isolates the second and discards the first. MT-2 is built around the first. They are opposite halves of one hormone.
Key facts
- Shared parent
- alpha-MSH, 1,664.9 Da
- KPV
- C-terminal tripeptide, 342.43 Da
- KPV keeps
- Anti-inflammatory activity
- MT-2
- Cyclic heptapeptide, 1024.2 Da
- MT-2 keeps
- Receptor-binding core
- Both unlicensed
- Yes
The hormone that does two things
Alpha-MSH drives pigmentation through melanocortin receptors and separately carries anti-inflammatory activity localised to its C-terminal end. Brzoska and colleagues titled their 2010 chapter terminal signal for that reason. Two activities in different regions of one thirteen-residue peptide.
How the two derivatives split it
KPV takes the last three residues (Lys-Pro-Val), keeping the anti-inflammatory activity and dropping the receptor-binding core entirely. MT-2 does the reverse, compressing the receptor-binding portion into a constrained ring and dropping the C-terminal tail. Each is defined by discarding what the other retained.
Research material referenced
MT-2 10mg, third-party HPLC tested
Why the size difference is so large
KPV at 342.43 Da is three residues with no modifications. MT-2 at 1024.2 Da is seven residues plus a lactam bridge, a D-amino acid, a non-standard residue and two capped termini. Three times the mass, because receptor engagement requires a specific three-dimensional presentation that three residues cannot provide.
What that says about fragment design
The activity you want determines how much molecule you need. An effect that runs through diffuse intracellular signalling can survive extreme truncation. An effect that requires binding a specific receptor pocket needs enough structure to present the right surface, which is why MT-2 is cyclised and constrained while KPV is a bare tripeptide.
Where they sit in this catalogue
Both are unlicensed everywhere. Both descend from a hormone whose other derivative, afamelanotide, is an approved medicine. Neither is that medicine. Reading them alongside each other is the clearest illustration on this site of how one parent molecule produces entirely different compounds depending on which of its functions is being pursued. KPV also appears as one component of the KLOW blend; MT-2 is only ever supplied alone.
Frequently asked questions
Why is MT-2 three times larger?
Receptor binding needs enough structure to present a specific surface. Three residues cannot do it; a constrained ring can.
Is either approved?
Neither. A third alpha-MSH derivative, afamelanotide, is approved, but that is a different molecule from both.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedBrzoska T et al., Terminal signal: anti-inflammatory effects of alpha-MSH. Adv Exp Med Biol 2010 (PMID 21222263)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · Melanotan II (CID 92432)pubchem.ncbi.nlm.nih.gov
- PubChemPubChem · Lys-Pro-Val (CID 125672)pubchem.ncbi.nlm.nih.gov
- PubChemPubChem · alpha-MSH (CID 16133793)pubchem.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More MT-2 (Melanotan II) articles
- Is Melanotan 2 Safe? What Has Actually Been PublishedCase reports of atypical melanocytic naevi following injection, and a 2022 review of the risks. What the dermatology literature has documented.
- Melanotan 2 Storage, Mixing and StabilityCyclisation, a D-amino acid and two capped termini make this among the most chemically stable peptides in the catalogue.
- Does Melanotan 2 Work Without UV?The receptor mechanism does not require UV, and the approved analogue proves pigmentation can rise without it. What that does and does not establish for MT-2.
- Melanotan 2 Onset: What Can and Cannot Be SaidNo controlled trial has measured a time course for MT-2. What melanin biology sets as a floor, and what the licensed analogue's data actually shows.
- Why This Site Publishes No Melanotan 2 DoseNot evasion - there is no established human dose to publish. The compound is unauthorised, the MHRA has warned about it, and the reported harms are specific.